Rocket Lab's Operational Momentum Collides With a Neutron-Sized Question Mark

Rocket Lab shares slide as Berenberg starts coverage with a buy rating and ARK buys, while a CFO share sale and Neutron delays weigh on sentiment.

Rocket Lab finds itself in an unusual spot: the rockets keep flying, the order book keeps swelling, and yet the stock keeps sliding. On Monday the shares changed hands at 53.10 euros, down 2.6 percent from Friday's close — a fitting snapshot of a company whose operational scorecard and market valuation have drifted in opposite directions.

The divergence is stark. Between mid-June and September 10, the equity shed roughly 39 percent, even as the broad S&P 500 added 2.4 percent over the same stretch. That gap points to company-specific headwinds rather than a souring macro backdrop. Over the past 30 days alone, the decline has run to about 21 percent.

Berenberg Plants a Flag at $83

Not everyone is running for the exits. On September 9, Berenberg initiated coverage with a buy rating and an $83 price target, arguing that the global space market could blow past the $1 trillion mark by 2030. The call landed alongside another vote of confidence: ARK Investment Management added roughly 681,000 shares within a two-day window, a move that suggests at least some institutional players view the recent weakness as an entry point rather than a warning.

The bulls, in other words, are treating the selloff as a dislocation. The bears have their own evidence.

A CFO Sale That Cuts Both Ways

Chief Financial Officer Adam C. Spice exercised employee options on 140,157 shares at $1.09 apiece on September 4 and sold them the same day at weighted average prices of $62.26 and $62.97, a transaction worth $8.78 million. He retains approximately 1.41 million shares.

Read one way, it's routine — U.S. executives exercise and sell options all the time, and such moves carry no automatic signal about confidence. Read another, the timing is awkward: the sale arrived in the middle of a stretch of heavy selling pressure. Both readings are defensible, which is precisely why the transaction has become a talking point rather than a verdict.

The Launchpad Tells a Different Story

Strip away the share-price noise and the operating picture looks considerably healthier. On Friday, Rocket Lab's "Happily Ever Faster" mission lofted the company's 16th Electron rocket of 2026 from Launch Complex 1 in New Zealand, deploying an Earth-observation satellite into a 500-kilometer circular orbit. The customer was not named.

That flight followed the September 2 "Owl Around the World" mission, the 94th Electron launch overall, which carried a StriX satellite for Japanese partner Synspective into low Earth orbit. Counting Friday's flight, Rocket Lab has now conducted 95 Electron missions in total — a cadence averaging more than one per month, a rate few competitors can match. Management has signaled another Electron launch before the month is out.

Solar Cells, Backlog, and the Case for Patience

Hardware beyond rockets is advancing too. On September 9 — the same day Berenberg published its note — Rocket Lab unveiled IMM Apex, a germanium-free solar cell for satellite and space applications designed to lessen reliance on scarce critical minerals. Media reports credited the announcement with lifting the stock before the opening bell, a sign that investors are watching for revenue streams beyond launch services.

The financial foundation, meanwhile, rests on a record backlog. When second-quarter 2026 results landed on August 10, Rocket Lab reported revenue of $234.07 million and an adjusted loss per share of $0.08. For the third quarter, management guided to revenue of $250 million to $265 million with a GAAP gross margin of 29 to 31 percent. The pattern is familiar for young space firms: growth is funded today, profitability arrives later.

Neutron: The Clock Is Ticking

All roads eventually lead to Neutron. The larger rocket is the vehicle that would transform Rocket Lab from a small-satellite specialist into a genuine contender for heavier payloads — and it is the reason investors have long paid a premium for the stock. A failed first-stage tank test already pushed the debut flight to the fourth quarter of 2026, and management has since described that window as "getting tighter." Delivery of the rocket to the launch pad is slated for the fourth quarter, but no fixed date exists for the maiden flight itself.

That uncertainty is what gnaws at the valuation. Every slip in the schedule erodes the premium the market once granted without hesitation.

What the Charts Say

The technical picture offers little comfort. The stock trades 14 percent below its 50-day moving average and 25 percent beneath its 200-day average of 70.34 euros. It sits 63 percent above its 52-week low of 32.60 euros, so the recovery from November's trough has not been fully erased. Since the start of the year, the shares are down 11 percent, and they remain 59 percent below their 52-week high of 133.80 euros. A relative strength index reading of 37.8 hints at oversold conditions — though that alone is no buy signal.

Friday's session offered a brief reprieve, with the stock gaining 2.1 percent to close at 54.50 euros.

For investors, the setup resists a clean narrative. A functioning launch business, fresh technology, and a record order book sit on one side of the ledger. On the other: an insider sale, a Neutron timeline that keeps slipping, and a share price that has spent months voting no. Berenberg's buy call and ARK's accumulation suggest that a slice of institutional money believes the market has overshot to the downside. Whether that bet pays off hinges on a rocket that has yet to leave the ground.